CYTK
Price
$62.03
Change
-$0.96 (-1.52%)
Updated
Nov 2 closing price
Capitalization
8.62B
One day until earnings call
Intraday BUY SELL Signals
TSHA
Price
$4.00
Change
-$0.13 (-3.15%)
Updated
Nov 2 closing price
Capitalization
1.3B
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

CYTK vs TSHA

CYTK vs TSHA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CYTK vs. TSHA commentary
Nov 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and TSHA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CYTK with price predictions
Nov 02, 2026

CYTK's RSI Indicator climbs out of oversold territory

The RSI Indicator for CYTK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 20 of the 24 cases the stock moved higher. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 68 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on October 13, 2026. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in 42 of 56 cases over the following month. The odds of a continued upward trend are 75%.

Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 215 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 78 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for CYTK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CYTK's P/B Ratio (-49.708) is slightly lower than the industry average of (3.104). P/E Ratio (-8.591) is within average values for comparable stocks, (-0.958). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (439.647).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for TSHA with price predictions
Nov 02, 2026

TSHA sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for TSHA moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 53 cases where TSHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TSHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TSHA's RSI Oscillator exited the oversold zone, 30 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TSHA as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for TSHA just turned positive on October 21, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.

Following a +7.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 213 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.365) is normal, around the industry mean (3.104). P/E Ratio (-9.756) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (439.647).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TSHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CYTK vs TSHA: Fundamental Ratings
CYTK
TSHA
OUTLOOK RATING
1..100
7217
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6078
P/E GROWTH RATING
1..100
2117
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TSHA's Valuation (23) in the null industry is significantly better than the same rating for CYTK (93) in the Biotechnology industry. This means that TSHA’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as TSHA (100) in the null industry. This means that CYTK’s stock grew similarly to TSHA’s over the last 12 months.

TSHA's SMR Rating (98) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that TSHA’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (60) in the Biotechnology industry is in the same range as TSHA (78) in the null industry. This means that CYTK’s stock grew similarly to TSHA’s over the last 12 months.

TSHA's P/E Growth Rating (17) in the null industry is in the same range as CYTK (21) in the Biotechnology industry. This means that TSHA’s stock grew similarly to CYTK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKTSHA
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 14 days ago
73%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Nov 03, 2026
Stock price -- (CYTK: $62.03 vs. TSHA: $4.00)
Brand notoriety: CYTK and TSHA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 83% vs. TSHA: 56%
Market capitalization -- CYTK: $8.62B vs. TSHA: $1.3B
CYTK [@Biotechnology] is valued at $8.62B. TSHA’s [@Biotechnology] market capitalization is $1.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $140.2B. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green while TSHA’s FA Score has 2 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • TSHA’s FA Score: 2 green, 3 red.
According to our system of comparison, TSHA is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while TSHA’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 4 bearish.
  • TSHA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CYTK and TSHA are a good buy in the short-term.

Price Growth

CYTK (@Biotechnology) experienced а +2.14% price change this week, while TSHA (@Biotechnology) price change was -0.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.92%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -20.21%.

Reported Earning Dates

CYTK is expected to report earnings on Nov 04, 2026.

TSHA is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-0.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CYTK
Daily Signal:
Gain/Loss:
TSHA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

TSHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TSHA has been loosely correlated with SLDB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if TSHA jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TSHA
1D Price
Change %
TSHA100%
-3.15%
SLDB - TSHA
53%
Loosely correlated
-3.23%
ABEO - TSHA
53%
Loosely correlated
-2.30%
STOK - TSHA
52%
Loosely correlated
+0.72%
MGTX - TSHA
51%
Loosely correlated
-1.79%
NGNE - TSHA
49%
Loosely correlated
-3.41%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BFST32.720.92
+2.89%
Business First Bancshares
KRG25.740.67
+2.67%
Kite Realty Group Trust
NU11.620.01
+0.09%
Nu Holdings Ltd
ZUMZ14.97-0.20
-1.32%
Zumiez
SMXT4.20-0.52
-11.02%
Solarmax Technology Inc